Biotechnology Industry in India

Biotechnology Industry in India

• Overview • Scope

• Career Opportunities

• List of Top Companies

• Other Biotech Companies

• Recent Developments

General Introduction of Biotech Sector Today the global biotech industry has nearly 1500 companies giving employment to over 1,79,000 people in the fields of manufacturing, sales, research, development and various other related jobs. The Indian biotech industry is expected to grow up to Rs. 4,40,000 crores by 2020.

Pie chart showing the market share of key biotech services in India

International Biotech Companies

Top Indian Biotech Companies

International Biotech Companies in India

Genentech Inc. Biocon Monsanto

Amgen Inc. Shantha Biotechnics Pfizer

Gilead Sciences Inc. Bharat Biotech Astra Zeneca

Genzyme Corporation Wockhardt Unilever

Serono S.A Dr. Reddy's Laboratories Dupont

Biogen Idec Inc. Serum Institute of India Bayer

MedImmune Inc. Zydus Cadila Eli Lilly

Chiron Corporation Aventis Pharma Hoechst Roussel Vet

Amylin Pharmaceuticals Inc.

Reliance Life Sciences Millipore

Invitrogen Corporation Novozymes

Biotechnology Sector: Introduction In 2006, India was ranked 3rd in the South-Eastern Asia region after Korea and Japan on the basis of number of biotech companies (Ernst and Young). India has about 280 companies in biotech sector. Biocon was ranked India’s largest biotech company and Rasi was the top Bt cotton producer in the group.

Sector Outlook Classification of Sector SWOT Analysis Evolution of Biotechnology With a record growth rate of about 37.42%, Indian biotech industry has achieved market value of US$ 1.45 billion (Rs. 6521 crore). It has been growing at the pace of 35-40% for the last three years and is estimated to grow to US$ 5 billion by 2010. The immense potential of the sector is clearly visible from its growth rate. Growing numbers of research laboratories, pool of qualified scientific talent, widening institutional network, vibrant clinical potential and fast growing pharma sector are the important growth stimulants. India’s ecological and population diversity has played a key role in the developments in the areas of research and drug discovery in biotech sector. Government is also supporting the biotech sector by providing financial and non-financial incentives at central and state level. Although Indian biotech industry is just 1.1% of the world biotech industry, India is soon going to become a prominent player. Today India is the favorite destination not only for biotech products, pharmaceuticals and diagnostics but also for outsourcing of contract research and clinical trials. According to the BioSpectrum-ABLE survey report in 2006:

BioPharma sector crossed the $1 billion (Rs 4,475 crore) mark, driven by exports worth Rs 2495.24 crore.

BioAgri sector recorded the highest growth.

The industry has shown 81 percent growth rate.

The popularity of Bt cotton helped the BioAgri sector to grow to Rs 598 crore from Rs 330 crore

Serum has shown Rs 703 crore in sales and is ahead of Biocon Ltd by Rs 15 crore.

Biotech Sector: Economic Outlook According to Dr Clive James, Founder and President of the International Service for the Acquisition of Agri- Biotech Applications (ISAAA), the period 2006-2015 has been projected as the "decade of Asia" in the field of biotechnology. Achieving US$ 1 billion mark with export accounting for US$ 756 million is an important milestone for the Indian biotech sector. Biotech companies are earning huge profits and are using these profits for further investments, e.g. Wockhardt acquired Pinewood Laboratories and Reliance Life Sciences took staked control of GeneMedix Plc. Some of the important points are:

BioAgri's share of exports reached to Rs 35.88 crore.

BioServices overseas revenues were Rs 684 crore.

Indian pharmaceutical industry is growing at the rate of over 8 per cent per year.

BioPharma exports amount to Rs 3,357.17 crore (74.33 percent of the total exports).

BioInformatics and BioIndustrial sector accounted for 3% and 1.23 % of the total exports respectively.

Ever-increasing investment levels (Rs 1,650 crore against Rs 1,215 crore previous year).

Investment of 25.3% of revenue in research and building infrastructure.

Western India is leading with revenues of Rs.3, 234.42 crore (49.6% of Indian biotech share).

Classification of Biotech Sector Biotechnology is defined as the technology that uses biological systems, organisms, or derivatives thereof, for the benefit of humankind. It is a powerful technology with the potential to transform many industrial sectors like forestry, fishing, pharmaceuticals and health, agriculture, textiles, environmental industries and energy and mining, etc. It can be classified as follows: • Modern Biotechnology: It is a recent, research based technology. It performs a range of activities in the areas of molecular and cellular biology, recombinant DNA technology, biochemistry, immunology, etc. • Gene Technology: It is a subset of biotechnology. It involves scientific manipulation of living organisms at genetic level to produce new vaccines, hormones, and monoclonal hormones. • BioPharma: Therapeutics, diagnostics, vaccines and animal health care products are its major products.

• BioIndustrial: It consists of organic amino acids, enzymes, and yeast and yeast-based products. • BioServices: It involves contract research, contract manufacturing and clinical research. • BioAgri: It comprises of biopesticides, genetically engineered seeds and biofertilisers. • Bio-IT: Products and services in bioinformatics represent this sector.

SWOT Analysis of Biotech Sector

STRENGTHS

• Highly skilled and qualified scientific manpower. • Government taking initiatives to support biotech sector • Capability in handling fermentation based compounds, extraction of high quality products using plant and animal parts. •Recombinant DNA technology, plant breeding techniques, plant cell/tissue culture, bioprocess engineering, use of cell/microbial culture techniques, etc. •Setting up of effective and efficient biotech enterprises. • Infrastructure in manufacturing processing equipments and bio-reactors WEAKNESSES

• Administration of resources supporting biotech research and development

• Lack of awareness regarding biotech practices OPPORTUNITIES • Accelerated growth of biotech industry • Increased opportunity of entrepreneurial activity • Population and ecological diversity THREATS • Lack of advanced biotechnologies and products • Lack of public awareness about biotechnology issues • Difference between theory and practice in R&D

Evolution of Biotechnology Biotechnology is a very broad term which is applicable to old and new, sophisticated and simple, familiar and strange applications of living organisms– anything from simple fermentation to sophisticated gene therapy. The evolution of the biotechnology sector is as follows: Ancient Biotechnology: Biotechnology is as old as the ancient culture of Indians, Chinese, Greeks, Romans, Egyptians, Sumerians and other communities of the world. Use of microorganisms for fermentation, domesticating animals for livestock, alcohol in the form of wine and beer, herbal remedies and plant balms for treatment of wounds and ailments are a few examples of ancient biotechnology. Pre-20th Century: Renaissance accelerated the pace of scientific discoveries in Europe. Galileo, Copernicus, Leonardo Da Vinci were some of the renaissance leaders whose knowledge extended over various branches of art, science and medicine. Microscope, first cork cell, protozoa,

smallpox vaccine, Darwin’s theory of evolution are some of the famous discoveries relating to this very field. 20th Century: In early 20th century modern biotechnology movement started, particularly in immunology and genetics. Penicillin, computers, discovery of DNA as the genetic basis, use of bacteria to treat raw sewage (bioremediation project) are significant developments in this direction. Revolution in forensics and biomedical science took place with the new lab methods, such as DNA Sequencing, protein analysis, Polymerase Chain Reaction (PCR). The millennium ended with the introduction of first cloned sheep Dolly, debate over the ethical issues relating to biotechnology, stem cell research, genetic testing and genetically modified organisms. 21st Century-Nanotechnology, Biotechnology, Cognitive and Information Sciences (NBIC): 21st century started with the development of rough draft of human genome, or map of human life. NBIC combines the knowledge of biotechnology generated in the past 30 years to develop abilities in computing advances (information technology), in manipulating matters at atomic level (nanotechnology), and in understanding human brain (cognitive sciences).

Scope of Biotechnology Sector.

In 1978, Circa was the only Indian biotech company that used to manufacture fermentations and enzyme products. Today, Indian biotech sector comprises of more than 280 companies, generating revenues of about US$ 1.5 billion. Indian biotech industry comprises of clinical research, new drug discovery, bioinformatics, contract R&D, biopharmaceuticals, etc. In India, Bangalore has emerged as the largest biotech hub with a total annual sales revenue of about Rs. 1400 crore.

There are about 175 companies working in the diverse areas of bioagri, bioindustrial, bioservices, nutraceutical, biopharma, bioinformatics, herbal products and biosuppliers. With the supporting policy framework, biogenerics or biosimilars, bio manufacturing, stem cells and regenerative medicine have been identified as areas of strategic importance. Biotech sector achievements are as follows:

• Biotech Industry has 37.42% growth rate per annum • Biotech industry has reached US$ 1.5 billion • Bioservices has reached US$ 160 million • Bioagri sector has crossed US$ 130 million • Biopharma has reached US$ 1billion

Biotechnology Sector: Future Scenario

Globally, Indian biotech industry has emerged as the manufacturer of novel and proprietary biotech products. The factors behind this success are specialized human resource, internationally benchmarked infrastructure and national biotechnology strategy. With 208 biotech companies and 180 bio-suppliers, Indian biotech industry is worth US$ 1.45 billion. Bio-partnering and co-developing technologies with American and Chinese companies will increase the scope of R&D in India. Emerging investment opportunities and increasing global visibility has forced Indian biotech companies to develop business models, improve product commercialization and make strong market position.

Infrastructure for R&D in protein engineering, molecular studies, immunological studies and drug designing is also developing. There is lot of scope in biogenerics sector as many biological drugs are going off-patent in coming years. Regulatory framework in association with strong biomanufacturing skills will help in getting approval for generic versions of biologicals e.g. GCSF, insulin, Hep B vaccine, etc. Jobs in Biotech Sector According to Dr Manju Sharma, former Director of Department of Biotechnology, Ministry of Science and Technology, New Delhi, biotech sector will become the largest sector for employment of skilled human resource in near future. There are huge career opportunities in new biology and new biosciences. Development of new scientific institutions and centers for excellence will help young students and scientists pursue careers in research and development. It will also help in entrepreneurial development in this sector. Biotech sector provides professional opportunities in the following areas: • Inventorisation, characterization and documentation • Plant and agriculture related activities • Testing of GMOs (Genetically Modified Organisms) and transgenics • Health care diagnostic • Industrial biotechnology • Environmental protection and Biodiversity conservation • Food processing • Production of biologicals and other biotech products • Teaching and training in biotechnology

Career Institutes for Biotech Career Development Biotechnology Sector: Employment Top Biotech Institutes in India

• Amity University, Noida, U.P. • Arunai Engineering College, Tiruvannamalai, Tamilnadu • Bioinformatics Centre, University of Pune, Maharashtra • Birla Institute of Technology, Mesra, Ranchi • BMS Institute of Technology, Bangalore • Centre for Biotechnology, Jawaharlal Nehru University, New Delhi • Department of Biochemical Engineering and Biotechnology, IIT Delhi • Department of Biotechnology, Cochin University of Science & Technology, Cochin • Department of Microbiology & Biotechnology Centre, The Maharaja Sayaji Rao University of Baroda, Baroda • Department of Plant Molecular Biology and Biotechnology, TN Agricultural University, Coimbatore • Garden City College, Bangalore • GM Institute of Technology, Devengare, Karnataka • Institute of Chemical Technology, University of Mumbai, Maharashtra • Jaypee Institute of Information Technology, Noida, U.P. • National Dairy Research Institute (NDRI), Karnal, Haryana • Presidency College, Bangalore • Rajiv Gandhi Centre for Biotechnology, Trivandrum, Kerala • School of Life Sciences, Hyderabad • Seeding Academy of Design, Technology and Management, Silas, Jaipur • Shree Manibhai Virani & Smt Navalben Virani Science College, Rajkot, Gujarat • The Oxford College of Science, Bangalore • University Institute of Engineering & Technology, Punjab University, Chandigarh

• University School of Biotechnology, Guru Gobind Singh IP University, Delhi Biotechnology Sector: Employment Biotech Jobs Biotechnology is a relatively new field. It is a very exciting sector with tremendous possibilities. It is an emerging field, yielding wonder drugs and new and improved varieties of plants and animals. By patenting their research, scientists get name as well as large fortunes as fruits of their research. Research Scientists not only perform experiments in labs but also devote much of their time in attending seminars, conferences, teaching university students, writing papers. Research scientist has a very creative role as he has to work on the forefront of scientific discovery. He has to decide what to study, how to study, and thereby he can learn new things. Laboratory Assistants and Lab Technicians work on a variety of sophisticated equipments, prepare chemicals, maintain experimental microbial, plant, or tissue culture in research labs. Lab technician helps research scientists in their scientific discoveries. Lab technician after doing MBA can get management position in a biotech firm. Sales Representatives try to sell the biotech industry products to doctors, farmers, other industries, or sell and supply scientific equipments to biotech researchers. Quality Assurance Technicians test the biotech products in labs or production facilities to ensure that they are safe and meet the required standards. BioInformatics Personnel work on designing and maintaining scientific data and analysing the results of various research

trials. Job Prospects of Biotechnology in India: As the biotech industry is growing and commercializing, the number of job vacancies is also increasing. Companies are staffing more and more sales force to push their products in the market. They are also employing trained people for clinical research so as to get through the clinical approval process. This has increased demand for clinical trial managers, clinical research professionals, clinical research associates and outsourcing managers. Because of commercialization of the industry, the demand for finance and administration personnel is also increasing. Thus, biotech companies are recruiting people at all levels. A biotechnologist may also work in government institutes and organizations. These days agriculture, dairy, horticulture and drug companies are also employing large number of biotechnologists. Biotech companies like Dr. Reddy’s Labs, Ranbaxy, Dabur, and Hindustan Lever have openings in their R&D facilities. The starting salary while doing fellowship in a research institute comes around Rs. 3,000 per month. Private companies pay around Rs. 5,000-10,000 per month to a qualified biotechnologist. Currently there is shortage of trained people in biotech field in India. To overcome the shortage, Department of Biotechnology is promoting this field in schools and colleges. Those who wish to work in this industry can go for a short-term training for biotechnologists, organized by Biotech Consortium India Ltd. According to an estimate, 300 biotech companies in India could provide employment to more than 20,000 students. At present India has a capacity of less than 700 post

graduate students spread over the various segments like agriculture, vaccine research, neurosciences, brain cell research, etc. Although the biotech industry hopes to touch US$ 25 billion mark by 2015, manpower shortage has emerged as a major problem that might derail its progress. Biotech industry survey done by BioSpectrum shows that despite the fact that over 200 biotech colleges are producing about 8000 fresh biotech graduates and post-graduates every year, the industry will face looming shortage of trained manpower. It points out the huge difference between the industry’s expectations and availability of quality manpower. The situation is aggravated by the fact that students from the top institutions prefer to go abroad for higher studies rather than taking jobs in India.

Top Players in Biotechnology

Novozymes Panacea Biotec Rasi Seeds Pvt. Ltd. Rossari Biotech Monsanto India Limited Shantha Biotechnics Limited Nuziveedu Seeds Limited Advanced Enzymes Technologies Limited Bharat Serums and Vaccines Limited Maharashtra Hybrid Seed Company (Mahyco)

Other Biotech Companies Avestha Gengraine Eli Lilly and Company (India) Pvt. Ltd. Haffkine Bio-Pharmaceuticals

Indian Immunologicals ltd. Krebs Biochemicals Metahelix Life Sciences Wipro Biomed

Recent Developments 1.Biocon granted marketing license of its cancer drug to Ferozsons labs Biocon granted exclusive marketing license of Biomab EGFR, biotech molecule for the treatment of cancer, to Ferozsons Laboratories Ltd of Pakistan. The Pakistan oncology market is valued at nearly $70 million. Biomab EGFR has entered the rapidly growing monoclonal sector that has annual growth rate of about 30%. Biomab EGFR is used in the treatment of neck and head cancer. 2.Favourable decision on Ranbaxy’s case Federal court of Canada read out a favourable decision on Ranbaxy’s case against Pfizer. Pfizer marketed Atorvastatin, cholesterol-lowering drug, as Lipitor. The Court invalidated Pfizer’s atorvastatin patent CA 2,021,546 as the data provided didn’t back up the suggestion of ten-fold increase in activity. On marketing approval, this decision will allow Ranbaxy’s generic atorvastatin to enter the Canadian market.

3.Ranbaxy launches asthma inhalation capsules On 29th March Ranbaxy launched Osovair, asthma inhalation capsule, which is a combination of long acting ß2 agonist Formoterol and the new inhaled corticosteroid Ciclesonide drugs. Osovair is available in Rheocaps as Osovair 160 mcg and Osovair 320 mcg and can only be used with Ranbaxy's Rheohaler, a capsule-based multidose dry-powder inhaler. 4.BT cotton to gain India’s cotton area According to Kishorilal Jhunjhunwala, president of the East India Cotton Association, the genetically modified cotton had covered 9.1 million hectares of total area for cotton production in 2006-07 with good yield and prices. The genetically modified cotton covered 35% of the total area with cotton yield rising to 500 Kg per hectare. Farmers are aggressively buying Monsanto Company’s BT cottonseeds, which help fight bollworms, a major worry for Indian farmers. It is estimated that the domestic cotton production will go up to 27 million bales and the total cotton export would cross 4 million bales by September 2007. But the environmental groups have opposed BT seeds claiming that they deplete bio-diversity. 5.Supreme court’s approval for conducting field trials The Supreme Court has given approval for conducting field trials of genetically modified seeds but with certain

restrictions. The genetically modified (GM) crops are expected to increase productivity, reduce crop losses due to worm attacks and lower pesticide use. This permission will help in large-scale field trials of BT brinjal of Maharashtra Hybrid Seeds Company (Mahyco). India is doing field trials of GM seeds of mustard, corn, cauliflower, brinjal, rice, etc and expecting to repeat the results of GM cottonseeds. The restriction came in the form of increase in the isolation distance between the GM crop fields and other fields. Earlier there was no such isolation restriction. The court said that a designated scientist would make sure that all the conditions are complied with during the trial. 6.Biocon granted marketing license of its cancer drug to Ferozsons lab To claim share in the drug distribution market, the Reliance Anil Dhirubhai Ambani Group (ADAG) is planning to have a tie up with a multinational distribution company MNC to float its pharma retail chain business. 7.Insulin created from child’s stem cells From the stem cells taken from child’s umbilical chord, scientists from the University of Texas Medical Branch at Galveston have successfully created insulin in lab. It is a medical breakthrough, a promise to cure Type 1 diabetes, which is a chronic lifelong disease that occurs when the pancreas does not produce enough insulin to properly control blood sugar levels. 8.First adult liver transplant in Bangalore On 20th April, first successful living donor liver transplant was carried out at Narayana Hrudayalaya in Bangalore. It

was a 17-hour split liver transplant surgery wherein a large chunk of the liver of the spouse (65% of the right lobe of liver) was transplanted into the husband suffering from cirrhosis of liver. 9.India lags behind in Biotech, says Ernst report According to the new study report by Ernst & Young, Indian Biotech industry is growing but it badly needs funds, especially during early stages of new drug development process, for the sustainable industry development. It should start filing more original patents in novel drugs too. The report also points to the possibility of India following the Japanese path and moving up the value chain of new drug development. 10.ASSOCHAM: Biotech sector to touch US$ 5 bn by 2009-10 According to ASSOCHAM, with a consecutive CAGR of 35.1%, the Biotech sector is expected to grow to US$ 5 billion by 2009-10. Accounting for 52% of the industry’s total revenue, Biotech sector exports are valued at US$ 763 million. With a growth rate of 36%, the investments in the sector have grown to US$ 360 million in 2005-06. Currently, there are more than 300 biotech companies focusing on different aspects of value chain and this figure is expected to double in the next 3-4 years. With a growth rate of 32%, Biopharma sector has grown to US$ 1 billion in 2005-06. It accounts for over 70% of domestic sales and 75% of total exports. Agri Biotech and BioServices are registering fastest growth and Vaccines and Bio-Generics are the common areas of interest for the

leading biotech companies. In coming 3-4 years, apart from the knowledge-based industry, a series of joint ventures will come up in application of biotechnology in horticulture, agriculture and viticulture. The sector has the potential to attract funding from international bodies like World Bank, International Finance Corporations, Ventures Capitals and Private Equity Arms. 11.Eli launches diabetes awareness camp On 28th May, Under ‘Peaks and Valley’s Complications Check’ (PVCC) programme, Eli Lilly announced that it has the target of providing free treatment to about 50,000 high-risk diabetes patients across the country in the next three years. This programme was launched on the occasion of ‘Insulin-discovery Week’. The company would shortlist patients through free medical checkups in 20,000 camps in 50 Indian cities, including the four metros. The camp would function in collaboration with private physicians and hospitals. At the PVCC programme, physicians would provide additional care in the form of comprehensive check-up packages that will include a test for eye and kidney problems and foot examination along with the usual blood glucose test. 12.Bangalore Bio 2007 starting from 7th June 2007 Bangalore International Exhibition Centre (BEIC) announced that in Bangalore Bio 2007, a three-day biotech event starting from 7th June 2007, 11 Indian states would present themselves as the ideal destination for setting up facilities for R&D in the biotech sector. The confirmed states are Andhra Pradesh, Chhattisgarh, Gujarat, Haryana, Himachal

Pradesh, Jharkhand, Kerala, Maharashtra, Orissa, Rajasthan and Uttar Pradesh. Key decision makers from these states will have the opportunity to absorb a superior content to make strategic decisions for the development of biotech industry in their respective states. This event is promoted by the Government of Karnataka and organized by Vision Group of Biotechnology 13.Two Indian projects shortlisted for Green Oscars Two Indian biotech projects, BIOTECH from Kerala and SKG Sangha from Karnataka, have been short-listed for the Ashden Awards for Sustainable Energy, popularly known as the “Green Oscars”. These projects will have to compete with the contestants from China, Ghana, Nepal, Peru, Bangladesh, Philippines, and Tanzania for five awards. The award and the prize money of more than 200,000 pounds (Rs. 17 lakhs approx) will be presented by Former US Vice president Al Gore at the Royal Geographical Society on June 21. 14.Zenotech setting up plasma fractional facility Zenotech Laboratories, Hyderabad based generic biopharmaceutical company, is planning to set up a plasma fractional facility at an investment of US$ 20-25 million. The facility will be engaged in disaggregating the various proteins in plasma. The global market size for plasma ingredients is estimated at US$ 20 billion, of which the main proteins including immunoglobulins have a market size of US$ 2 billion. Sources said that the possible locations for the facility are Vizag and Vijayawada. The company already has three facilities in Hyderabad. The proposed facility would be in compliance with the US/EU regulatory standards.

15.Lupin and Wockhardt got USFDA approval Lupin and Wockhardt got USFDA nod for Cefadroxil and anti-fungal drug. India’s Lupin Ltd. got US FDA approval for its generic antibiotic Cefadroxil capsules whereas drug maker Wockhardt received USFDA approval to enter the market for Lamisil, an anti-fungal drug. 16.US drug co plans to recall contact lens care solution Advanced Medical Optics Inc (AMO), US-based ophthalmic drug major, has decided to withdraw its contact lens care solution AMO Complete Moisture Plus from the Indian market on grounds of its adverse reaction in US market. According to the US Centers for Disease Control & Prevention (CDC), the drug triggers a rare but serious eye infection, Acanthamoeba Keratitis (AK). AK may lead to vision loss with some patients requiring a corneal transplant. The consumers who used Complete Moisture Plus solution have seven times greater risk of developing AK. The USFDA has advised consumers to replace their lenses and storage containers who have used AMO’s solution. The symptoms of Acanthamoeba Keratitis can be similar to those of other more common eye infections and may include eye pain or redness, blurred vision, light sensitivity, sensation of something in the eye or excessive tearing, but Acanthamoeba is more difficult to treat. 17.Glenmark eyes pain management market

Glenmark’s Swiss subsidiary has completed phase I clinical trials for a pain reliever, GRC 6211, and is planning to launch the molecule in 2011. GRC 6211 is an antagonist compound for a range of pain indications like osteoarthritis, urinary incontinence and naturopathic pain. Glenmark is in discussions with the potential partners for licensing this compound. Pain management has a large unmet market and companies are trying to capture this large market. Merck, GSK and Pfizer also have molecules under development in the same category. 18.Aurobindo gets US FDA nod for Cefprozil tablet Aurobindo Pharma, Indian drug maker, received USFDA nod for its Cefprozil tablet – a second generation cephalosporin antibiotic in strengths of 250 and 500 mg. This approval will help Aurobindo to enter the US$ 80 million market of antibiotic Cefzil in the US.

TOP PLAYERS

1. Novozymes Novozymes is a leading biotech-based company in enzyme and microorganism segment. It is present in over 40 different industries and 130 countries and is marking its presence in India through Novozymes South Asia Pvt. Ltd. Its product portfolio includes over 100 types of enzymes and microorganisms and about 700 different products. Novozymes has state-of-art expertise in biotechnology, microbiology and gene technology and spends about 11-13% of sales on R&D. It has biotechnology as the core competence, as it helps Novozymes to discover, develop and produce enzymes and microorganisms as per the customer needs. Core competencies of Novozymes are as follows:

• Genetic & biochemical diversity • Strain development & improvement • Protein chemistry • Pathway engineering • Large-scale production • Protein design Novozymes has employee strength of about 4000 in 30 countries. There are about 47% in Production & Quality, 33% employees in Sales & Marketing and Administration, and the remaining 20% are in Research & Development. Board of Directors • Steen Riisgaard, President & CEO • Anna Lise Mortensen Grandjean, Vice President-Stakeholder Communication & Sustainability Development • Nickie Inger Spile, Vice President-People & Organisation

• Benny D. Loft, Executive Vice President & CEO-Finance, IT and Legal • Per Falholt, Executive Vice President & CSO-Research & Development • Peder Holk Nielson, Executive Vice President-Sales & Marketing • Arne W. Schmidt, Executive Vice president-Development, Production & Quality Contact Address: Novozymes Krogshoejvej 36 DK-2880 Bagsvaerd Phone: +45 88 24 99 99 Website: www.novozymes.com

2. Panacea Biotec

Panacea Biotec is a leading biotech company with focus on the research, manufacturing and marketing of biopharmaceuticals, natural products and vaccines and new chemical entities. Panacea has achieved a growth of about 48.9% with a turnover of Rs. 6112.2 million during the year ending on 31st December 2006. It has been ranked 3rd among biotech companies and 6th among the pharmaceutical companies in India. Panacea has launched almost 43 brands in various therapeutics segments like immuno-suppressants, anti- osteoporosis, pain management and anti¬¬- diabetics. It has marked its presence in the markets of Africa, CIS, Middle East Asia, Uzbekistan, China, Myanmar, Thailand, and Bangladesh, Cambodia, and Malaysia. It has entered into an in-licensing arrangement with National Institute of Health, USA for peptide-based products, and strategic collaboration with UK based Cambridge Biostability Ltd. for development of new vaccine delivery system. With intellectual property of about 200 scientists, the company has two state-of-art R&D facilities in Delhi and Punjab. It spends almost 6% of its net sales on R&D. Its Pharmaceutical and Vaccine formulation plant in New Delhi has WHO-cGMP certification. Now it is planning to increase the number of scientists to 500 and R&D facilities to 5. The R&D at panacea is focused on:

• New Drug Discovery Research (NDDR) • Formulations Research (Drug Delivery Technologies) • The Advanced Drug Delivery Research Centre

• Bio-pharmaceutical Research (Newer Vaccines, Peptides & Monoclonal Antibodies) • Newer & Combination Vaccines Products: 1. Nimulid Tablets 2. Nimulid Safeinject 3. Panimun 4. Alphadol 5. Enivac HB 6. Manyana Tablets 7. Bukatel 8. ZINC-Naproxen 9. 0394 10. Rifampicin 11. Lovastatin + Niacin-ER 12. Atorvastatin and Ezetimibe 13. Mirtazapine 14. Tacrolimus 15. Ciprofloxacin + Ornidazole 16. Glizid MR 17. Betaglim Board of Directors A. Whole-Time Directors (Promoters) 1. Mr. Soshil Kumar Jain, Chairman 2. Mr. Ravinder Jain, Managing Director 3. Mr. Rajesh Jain, Joint Managing Director 4. Mr. Sandeep Jain, Joint Managing Director 5. Mr. Sumit Jain, Director - Operations & Projects B. Non-Executive Directors (Under Corporate Governance) 1. Mr. Sunil Kapoor, Director 2. Mr. R.L. Narasimhan, Director 3. Mr. N.N. Khamitkar, Director 4. Mr. M.L. Kalra, Director 5. Mr. Gurmeet Singh, Director

6. Mr. K.M. Lal, Director 7. Dr. A.N. Saksena, Director Contact Address: Head Office B-1 Extn. / A-27, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi- 110044, India. Phone: +91-11- 41678000, 26945270, 26974500 Fax : +91-11-41679081 Email: [email protected] Website: www.panacea-biotec.com

3. Rasi Seeds (P) Ltd

Rasi Seeds was founded by Mr. M.Ramasami in 1973 in Attur located in Salem district of Madras. Initially it was into research and development in cotton seeds, and now it is into multi-crop, multi-location quality research movement for the benefits of farmers. The R&D facility of Rasi has got recognition from Department of Scientific and Industrial Research, Ministry of Science and Technology, Government of India. It is a 140 acres research farm with 55,000 sq.ft. for Green House. It has state-of-art biotech facility, fiber testing lab (HVI) and seed testing lab. Rasi has the proprietary cotton hybrid viz. RCH 2 Bt. It has developed about 1150 cotton hybrids of different characteristics. In 1999, Rasi and Monsanto tied-up for the commercialization of hybrid cotton with Bollgard technology. Rasi has about 10,000 farmers for direct seed production. It arranges pre-season technical meeting with the seed grower farmers so as to get the best quality and more productivity. Its product list includes:

• Cotton • Sunflower • Vegetables • Maize • Pearl Millet • Paddy Contact Address: Rasi Seeds (P) Ltd 273, Kamarajanar Road P.O. Box No: 30,

Attur – 636 102 Salem District, Tamilnadu, India. Phone: +91-4282-241007, 242007 Fax: +91-4282-242558 E-mail: [email protected] Website: www.rasiseeds.com

4. Rossari Biotech India Pvt. Ltd Rossari Biotech India Pvt. Ltd is the largest manufacturer of enzymes and among the leading specialty chemical manufacturers for textile processing. It was established in 1997 and has recently got ISO 9001: 2000 certifications. Rossari is in the business of designing, manufacturing and marketing of enzymes and textile auxiliaries. It exports its products to Sri Lanka, Bangladesh, UAE, Australia, Malaysia, Kenya, New Zealand, Jordan, China, Venezuela, and Nepal. Rossari has its corporate office in Mumbai and factory at Nhavasheva port, near Mumbai. Its R&D centre is in New Mumbai. Its product range includes Fragma, Flameshield, Hydrogard, Fabshield and Snocool as well as high concentrates and standard formulations of Acid cellulose, Neutral Cellulose, High Temperature Stable Amylases and Catalyses, Engineered Acid Cellulose (for low colour loss) Amylases. Its product range is as follows:

• ANTIFUNG SP Conc • D soft New • Dymax NDA • Newfade PUN Pdr • Temper VLF New liquid • Temper VLF New • Zycol SNE SU • Zywet P 100

Contact Address: Rossari Biotech India Pvt. Ltd 401, Omega, Main Street, Hiranandani Gardens, Powai, Mumbai - 400 076. Phone: 91- 22- 2570 9200 / 2570 9201 Fax : 91- 22- 25709210 Email: [email protected] Website: www.rossari.com

5. Monsanto India Limited

Monsanto began its work in India about 50 years back, soon after independence. It is into the business of agricultural inputs. Machete, first rice herbicide, was launched by the company in 1975. The company is functioning dedicatedly to develop high-yield crop varieties and hybrid crops. Over the years it has provided enduring solutions to the farmers. Monsanto India is an informal, flat, and team based organization that empowers employees and provides opportunities for personal as well as professional growth. It is working with the steady drive to be the leader in innovation, technology and market share. Using innovative technology, Monsanto provides integrated solutions to the farmers worldwide, thereby helping them to produce quality food and fibre. It has a research centre in Bangalore with state-of-art facilities. It covers an area of about 50,000 sq.ft. and has about 50 scientists, assisted by software programmers, administrators and consultants. Executive Officers

• Hugh Grant, Chairman, President and Chief Executive Officer • Brett D. Begemann, Executive Vice President, International Commercial • Carl M. Casale, Executive Vice President, North America Commercial • Richard B. Clark, Vice President and Controller • Terrell K. Crews, Executive Vice President and Chief Financial Officer • Scarlett Lee Foster, Vice President, Investor Relations • Dr. Robert T. Fraley, Executive Vice President and Chief Technology Officer • Janet M. Holloway, Vice President and Chief of Staff

• Mark J. Leidy, Executive Vice President, Manufacturing • Steven C. Mizell, Senior Vice President, Human Resources • Cheryl Morley, Senior Vice President, Corporate Strategy • Robert A. Paley, Vice President and Treasurer • Nicole Ringenberg, Vice President, Finance • David F. Snively, Senior Vice President, Secretary and General Counsel • Gerald A. Steiner, Executive Vice President, Commercial Acceptance Products I. Farm Inputs:• Round up: Broad Spectrum Herbicide • Machete: Transplanted Rice Herbicide • Fastmix: Transplanted Rice Herbicide II. Seeds: A. Maize: Maize hybrids are available under the umbrella brand name DEKALB. DEKALB Maize Hybrids • SUPER 900M • HI-SHELL • ALLROUNDER B. Sunflower: Sunflower is available under the umbrella brand name ASGROW. ASGROW Sunflower Hybrids • SH 3322 • SH 41 • SH 177 C. RICE: Rice is sold under the umbrella brand name FRONTLINE.

FRONTLINE Hybrid Paddy Seeds • RH 257 • RH 664 Contact Address: Monsanto India Limited Ahura Centre, 5th Floor 96, Mahakali Caves Road Andheri (East), Mumbai 400 093 India Phone: 91 22 28246450 / 67029851 Fax: 91 22 28244707 / 67023361 Email: [email protected] Website: www.monsantoindia.com

6. Shantha Biotechnics Limited Shantha Biotechnics Limited In 1993, Shantha Biotechnics limited was founded by Dr. K I Varaprasad and Dr. Varaprasad with the aim of manufacturing efficient and cost effective therapeutics and vaccines. It develops and manufactures health care products using biotechnology techniques. Its products are supplied to markets of Africa, Asia-Pacific, CIS and Latin America as well as to UNICEF and PAHO. The company’s R&D center at Shantha is equipped with the latest instruments and other facilities. It focuses on the development of proteins and vaccines, generic biologicals and novel therapeutic antibodies. It undertakes contract research in the areas of:

• Monoclonal antibody development • Gene cloning • Analytical method • Expression and purification of recombinant proteins by fermentation • Development of WCB and MCB • Fermentation/Purification Process optimization • Development of polyclonal antibodies WHO has pre-qualified SHANVAC-B, Hepatitis-B vaccine being manufactured by Shantha. In November 2006 Shantha Biotechnics Limited became part of France based Merieux Alliance group. The group has employee strength of 9,000 people worldwide and turnover of about US$ 1.3 billion. Board of Directors • Mr. Georges Hibon, Chairman • Dr. K.I. Varaprasad Reddy, Managing Director

• Mr. Khalil Ahmed, Executive Director • Mr. Alain Merieux, Director • Mr. Philippe Sans, Director • Mr. Johannes Burlin, Director • Mr. Abhey Yograj, Director • Mrs. Harsha Bangari, Director (Exim Bank Nominee) Products • Shanvac-B (r-DNA Hepatitis B Vaccine) • Shanferon (recombinant interferon Alfa 2b) • Shankinase (recombinant streptokinase) • Shanpoietin (recombinant human erythropoietin) • Shantetra (DPT +H vaccine) • CYTOCREST (Range of therapies in cancer care) • Elisa Kits Contact Address: SHANTHA BIOTECHNICS INDIA 3rd Floor, Serene Chambers, Road No.7, Banjara Hills, Hyderabad - 500 034 INDIA. Phone: +91-40-23543010, 23548507, 23608843 Fax: +91-40-23548476 E-mail: [email protected] Website: www.shanthabiotech.com

7. Nuziveedu Seeds Limited (NSL)

Nuziveedu Seeds Limited has emerged as a leading Agri-Biotech company. It has about 35% of the market share in the hybrid cotton seed market in India. It has developed its core capabilities in research, production, quality assurance and marketing. Nuziveedu is mainly into the business of seeds, but has also entered other fields of power, sugar, spinning/textile, etc. It has a customer base of about 65 lakh farmers, marketing network of 1395 distributors & dealers and over 20000 sub-dealers in 12 states of the country. Nuziveedu Seeds Limited was founded in 1973 with the aim of manufacturing good quality seeds. Mr. M. Venkataramaiah is the Founder and Chairman of Nuziveedu Seeds and Mr. Prabhakar Rao joined the company as Managing Director in 1982. Nuziveedu has R&D center at Kompally, and research farms at Hyderabad, Nizamabad, Gurazala, Guntur and Gurgaon. It has GOT farms for genetic purity testing at Guntur, Nuziveedu, Medak, Nizamabad and Hyderabad. Products COTTON• NCS-145 (Bunny & Bunny Bt) • NCS 207 (Mallika & Mallika Bt) SORGHUM • NSH 27 (Sona) • NSH 36(Bhagyasree) MAIZE • NMH-589 (Suvarna)

• NMH 145 (Ajay) • NMH-234 (Kamadhenu) SUNFLOWER • NSFH 36 (Sreshta) • NSFH - 9 (Mangala) PEARL MILLET • NBH-1035(Shanti) • NBH-2123(Revathi) • NBH-252 (Pandhari) Vegetables TOMATO • Tomato hybrid Surya • Tomato hybrid NTS 608 BRINJAL • NBH 696 • NBH 750 (Mahanandi) CHILLIES • NCH 1233 (Siri) • NCH 1236(Sampada) PADDY • NP-360(Moti) • NP-950 (Sourabh) • NP-45 (Harsha) Contact Address: Corporate Office: SECUNDERABAD: Nuziveedu Seeds Limited 7c, Surya Towers, 105, S.P.Road, Secunderabad-500 003. Ph: 91-40-27898008, 55334300 Fax: 55321500 E-mail: [email protected] Website: www.nuziveeduseeds.co.in

8. Advanced Enzymes Technologies Limited

Advanced Enzymes Technologies Limited was founded by Mr. L.C. Rathi in 1989 with the aim of providing eco-friendly solutions to all industrial problems as well as for the healthcare related problems. This research-based company has achieved market leadership in manufacturing of probiotics and enzymes. With its far-reaching experience in biotechnology, Advanced Enzymes has established its presence across 30 countries and 25 industries. Advanced Enzymes has its head office in Mumbai and a team of 180 people worldwide. Its R&D team, comprising of biochemists, microbiologists, food technologists and chemical engineers, is focused on New Application Development. It has achieved specialization in providing individual specific enzyme solutions. The R&D team of Advanced Enzymes is headed by Mr. Vic Rathi (Chairman) and Mr. C.L. Rathi (Managing Director) who are experts in the Enzyme Industry. Its rapidly expanding range of products includes different types of carbohydrases, cellulases, proteases, lipases and amylases. Products & Solutions

• Agriculture • Animal Nutrition Healthcare • Bakery Industry • Brewery Distillery • Environment Management • Fruit Juice Processing • Leather • Pharmaceuticals • Starch Processing • Tea Processing • Textile Processing

Contact Address: Advanced Enzymes Technologies Ltd. 'A' Wing, Sun Magnetica, 5th Floor, Accolade Galaxy, LIC Service Road, Louisewadi, Thane 400 604. Telephone: +91-22-2583 8350 –54, +91-22-25830188. Fax: +91-22-25835159. Website: www.enzymeindia.com

9. Bharat Serums and Vaccines Limited (BSV)

Bharat Serums and Vaccines Limited (BSV), established in 1971, aimed to develop specialized health care products for the quality conscious market. It manufactures and market biologicals, biotechnology products and pharmaceuticals. With a CAGR of about 50% for the last three years, Bharat Serums and Vaccines Ltd. is one of the fastest growing pharmaceutical companies in India. Currently, it holds a major market share of plasma derivatives and by introducing new and improved therapies it is increasing its range of products. It has a product portfolio of about 25 brands. Bharat Serums has two manufacturing sites at Thane and Ambernath. Its R&D is focused on developing superior drug delivery systems, creating IPR, improving existing products, and using emerging biotech tools for monoclonal antibodies and recombinant products. It is spending almost 7% of its turnover on R&D. BSV offers a wide variety of career opportunities and benefit packages. It treats employees as valued asset. It has talent from diverse backgrounds so as to have expertise, imagination and dedication for prosperous tomorrow. The Board of Directors of Bharat Serums and Vaccines comprises of the following: Dr. Vinod G Daftary, Chairman Emeritus Mr. Bharat V. Daftary, Chairman and Managing Director Dr. Gautam V. Daftary, Managing Director Mr. Nilesh R Ganjwala, Finance Director Mr. Shahzaad Dalal, Nominee Director, ILFS Investment Managers Limited Dr. Dilip Mehta, Professional Director

Mr. Prakash Shah, Professional Director

Products

• Plasma Derivatives • Monoclonals • Equine Antitoxins and Serums • Cardiovascular • Antifungals • Anaesthetics • Hormones Contact Address: Bharat Serums and Vaccines Limited Hoechst House, 16th Floor, Nariman Point, Mumbai – 400021. Maharashtra, India. Tel. No.: 91-22-56560900 Fax. No.: 91-22-56560901 E-mail: [email protected] Website: www.bharatserums.com

10. Maharashtra Hybrid Seed Company (Mahyco)

Maharashtra Hybrid Seed Company (Mahyco) was founded by Dr. Badrinarayan R. Barwale in 1964. Mahyco has endeavored to produce high quality hybrid seeds and is engaged in research area of plant generics. It is the first private enterprise in India to manufacture and market hybrids of sunflower, pearl millets, cotton, sorghum and wheat. With the use of gene transfer technology, it is trying to develop genetically enhanced crops. In 2002, it became the first Indian company to commercially grow and market transgenic crop - Bollgard cotton. Today, it is into research, production, processing and marketing of about 115 products in 30 crop species, including oilseeds, fibre, vegetables and cereals. Mahyco has research facility at Dawalwadi near Jalna (Maharashtra). It has the largest multi-locational ISO certificate (covering 59 locations). There are about 100,000 farmers working in its production centres. It has a network of 30 production centres and over 5000 sales outlets. In 1999, quality assurance laboratory of Mahyco became a member laboratory of International Seed Testing Association (ISTA), Zurich, Switzerland and in April 2007, it got the status of ISTA accredited laboratory. This lab offers facility of seed testing and issues blue, green and orange ISTA International Seed Analysis Certificate for Germination, Physical purity, Moisture and Determination of other seeds (OSD). At Mahyco plant biotechnology is an integral part of plant breeding programs. Traits of value are the focus of biotech research. Major research areas include:

• Crop Transformation • Molecular Virology • Molecular Microbiology • Gene Discovery and Molecular Markers • Entomology Contact Address: Maharashtra Hybrid Seed Company, Dawalwadi, PO Box 76, Jalna, India 431203 E-mail: [email protected] Phones (Research): +91-2482-262371-75, 262001 Phones (Marketing): +91-2482-233881, 233882 Fax: +91-2482-262002 Website: www.mahyco.com

11. Avestha Gengraine

Avestha Gengraine Technologies Pvt. Ltd. is a fully integrated biotechnology and bioinformatics company focusing on the development of preventive personalized medicines by achieving convergence between food, pharmaceuticals and clinical genomics. In 2006 the company had achieved turnover of Rs.18 crore and operating profit of Rs.1.8 crore and is expecting a turnover of about Rs.35-40 crore in 2007. Avesthagen was founded in 1998 by Dr. Villoo Morawala-Patell. It has 4 main strategic business units, viz. Biopharmaceuticals units, Biotherapeutics units, Food for medicine (FFM) unit, and Agri-biotech unit. Today it has a dedicated team of about 250 employees of which more than 25 are PhDs. It has 55 patents in the agri-biotech business. In 2003, Avesthagen got US patent for genetically modified technology for every commercially available hybrid seeds. Avesthagen has a world class, state-of-the-art laboratory at the International Tech Park in Bangalore. ICICI Ventures, Cipla Ltd., Tata industries, Godrej Industries and bioMérieux (France) have invested in Avesthagen. Its R&D is focused on:

• Transcriptome (Expression) Analysis • Bioinformatics • Metabolome Analysis and Lead Optimization • Genome Analysis • Recombinant Protein Expression In 2007, Avesthagen raised Rs. 150 crore from Groupe Limagrain, Groupe Danone and other strategic investors. Currently, Jacob Ballas Capital is planning to take a minority stake in Avesthagen with an investment of US$ 10 million.

Avesthagen is investing Rs.100 crore in expansion and new research projects in Hyderabad.

S.no

Job Title Qualifications Experience Job Responsibility

1

Manager - Biopharmaceutical Process Development

M.Sc/PhD (Molecular Biology/Cell Biology)

7-12 years experience in reputed pharma company

Optimization of Upstream & Downstream process and scale up. Responsible for setting up cGMP Process Development Lab.

2

Research Associate - Upstream Process Development

M.Sc. (Molecular Biology/Cell Biology)

Minimum 1-2 years of experience in mammalian cell culture and mammalian fermentation

3

General Manager - Clinical Trials

M.Sc./PhD in Life Sciences

Minimum 8 years of experience in the Biologics/Pharmaceutical industry. Including

Develop and implement protocols, lead and manage CRO relations

monitoring and managing clinical trials of new vaccines or drugs

4

Project Manager - Clinical Trials

M.Pharm/M.Sc/MVSc/MBBS with MD

Minimum 5 years experience in Clinical Pharmacology, Well versed with Clinical drug development process

Responsible for Biopharmaceuticals and Bionutritional clinical trials, Develop and implement protocols, GCP.

5

Project Manager - Upstream Process Development

M.Sc./PhD (Molecular Biology/Cell Biology)

Minimum 3-4 years of experience in mammalian cell culture and mammalian fermentation.

Interested candidates can apply for the above jobs by registering themselves on the career page at www.avesthagen.com or by mailing their resumes to [email protected]

Board of Directors 1. Mr. Darius E. Udwadia - Chairman 2. Dr. Villoo Morawala Patell - Founder, Vice Chairperson & Managing Director 3. Dr. Simon G. Best- Director 4. Dr. Marc van Montagu- Director 5. Dr. Barry Furr - Director 6. Mr. Nadir Godrej- Director 7. Mr. Aluri Srinivasa Rao - Director 8. Mr. Koen Wentink- Director 9. Ms. Farah Morawala Patell- Director Contact Address: Avestha Gengraine Technologies Pvt. Ltd. "Discoverer", 9th Floor, Unit 3 International Technology Park Whitefield Road, Bangalore 560066, India Tel: +91-80-2841 1665/2308/2770/2766 Fax: +91-80-2841 8780 E-mail: [email protected] Website: www.avesthagen.com

12. Eli Lilly Eli Lilly was founded by pharmaceutical chemist, Eli Lilly, on 10th May 1876. Its global headquarters are at Indianapolis, Indiana (USA). In 2006 it had achieved revenues of about US$ 15.57 billion. It has worldwide employee strength of over 41,502, of which over 8,262 are engaged in R&D activities. In 1923, Eli Lilly commercially manufactured and marketed Iletin, the first insulin product. Eli Lilly has manufacturing facilities in over 30 countries, R&D facilities in 9 countries and conducts clinical research in more than 50 countries. Its products serve markets of about 143 countries. It spends about US$ 3129 million per year on R&D. Eli Lily and Company (India) Pvt. Ltd. is a subsidiary of the US pharmaceutical company, Eli Lilly and Company. It was established in 1993 as Eli Lilly Ranbaxy Ltd, a 50:50 joint venture between Eli Lilly and Ranbaxy Laboratories Ltd. With the acquisition of 50% stake from Ranbaxy in 2001, Eli Lilly and Company created its Indian subsidiary as Eli Lilly and Company (India) Ltd. In India, Eli Lilly has employee strength of about 550, which includes more than 20 clinical research professionals. Its revenues grew to Rs. 150 crore in 2003 from Rs. 8 crore in 1994. On 24th March 2007, it announced donation of US$ 50 million to fight TB infections in India. About 14 public and private organizations will join the company as international partners in this campaign. Executive Management Rajiv Gulati, Chairman and managing Director-Eli Lilly India

Pvt. Ltd. Sidney Taurel, Chairman and Chief Executive Officer John Lechleiter, President and Chief Operating Officer Scott Canute, President, Manufacturing Operations Bryce Carmine, President, Global Brand Development Teams Deirdre Connelly, President, Lilly USA Newton F. Crenshaw, President and General Manager, Lilly Japan Patrick James, President, Elanco Animal Health Peter Johnson, Executive Director, Corporate Strategic Planning Lorenzo Tallarigo, President, International Operations Jacques Tapiero, President, Intercontinental Operations Products: Huminsulin Xigris Gemcite Distaclor ReoPro Alimta Contact Address: Eli Lilly and Company (India) Pvt. Ltd. Plot # 92, Sector 32, Institutional Area, Gurgaon-122001 HARYANA, INDIA Phone : 91-124-2823000,01 Fax : 91-124-2823012, 13 Email : [email protected] Website: www.lilly.com

13. Haffkine Bio-Pharmaceutical

Haffkine Institute was founded by Dr. Waldemar Mordecai Haffkine on 10th January 1899. It is located in Parel in Mumbai. In 1975, it was divided into Haffkine BioPharmaceutical Corporation Ltd and Haffkine Institute of Training, Research and testing, focused on vaccine production and research. Recently, it has been short-listed by the Maharashtra government as the future institution for providing clinical trial training to doctors, pharmacologists and scientists across India. Haffkine BioPharmaceutical Corporation Ltd developed first indigenous oral polio vaccine (OPV). Owing to strategic planning and sustained efforts, the company has been increasing its profits since 1997-98. It had employee strength of about 600 in 2001-02. Its R&D laboratory in Pimpri has been producing antitoxins and sera for scorpion and snake venom, diphtheria and tetanus toxins. It has a well-equipped animal-breeding lab in Mumbai. In 1977, Haffkine Ajintha Pharmaceuticals, a subsidiary in collaboration with Western Maharashtra Development Corporation Ltd, was established in Jalgaon. It produces capsules, tablets, powders, etc., which are supplied to Maharashtra government institutions and hospitals. Haffkine Bio-Pharma's ProductsS.no Job Title

Viral vaccines: Other formulations

Poliomyelitis vaccine (oral) Tablets:

Calcium with vitamin d nfi

Antitoxins & sera: Iron and folic acid ip

Snake antivenin Paracetamol ip.

Antiscorpion venom serum Vit b complex (t) nfi

Poly vitamin nfi

Bacterial vaccines:

Plague vac. I.p. Capsules:

Tetracycline ip.

Injectables:

Adrenaline tartrate inj. Ip Antiseptic:

Morphine injection ip. Haffkinol liquid

Haffkinol cream

Liquid orals:

Paracetamol syrup

Protonic h syrup Contact Address: Haffkine Bio-Pharmaceutical Acharya Donde Marg, Parel, Mumbai, India Tel. No.: 091- 22 4129320-22, 4129224 Fax 091-22-4168578 e-mail: [email protected] Website: www.vaccinehaffkine.com

14. Indian Immunologicals Ltd Indian Immunologicals Ltd. (IIL) was founded by National Dairy Development Board (NDDB) in 1982 with the aim of providing foot and mouth disease (FMD) vaccines to the farmers at affordable prices. The technology for FMD vaccine production was imported from M/s. Wellcome Foundation Limited, UK. In 2003, it invested Rs. 50 crore to set up an R&D facility in Hyderabad. IIL’s manufacturing facility in Hyderabad has the capacity to produce 80 million trivalent doses of FMD vaccine. It has WHO-GMP and ISO-9001:2000 certified plant in Ooty for the production of veterinary vaccines. In 1989, IIL launched first tissue culture vaccine-Raksharab. In 2006 it achieved sales turnover of Rs. 100 crores and became the 4th largest company in domestic animal healthcare market. It had launched Elovac-B, r-DNA Hepatitis-B vaccine, first vaccine from the Human Vaccine manufacturing Plant in Hyderabad. It exports products to the Gulf, Asian and African markets. In 2006, it entered into collaboration with RxKinetix to develop thermostable vaccines with improved stability at non-refrigerated temperatures. Its product portfolio in human vaccines includes MMR, DPT, Hepatitis B, Rabies and Measles whereas its veterinary vaccines include anti-rabies vaccine, canine vaccines, Foot and Mouth (FMD) vaccine, bacterial vaccine and various other combined vaccines. Board of Directors Dr. Amrita Patel, Chairman, IIL and NDDB Mr. Deepak Tikku, Director, IIL and Managing Director of NDDB Mr. K V Balasubramaniam, Managing Director, IIL

Prof. G. Padmanaban, Director, IIL Mr. A M M Sarma, Director, IIL Dr. V A Srinivasan, Director (Research) Contact Address: Indian Immunologicals Ltd. Road # 44, Jubilee Hills Hyderabad - 500033 Andhra Pradesh, India Tel: +91 40 23544585 +91 40 23544593 +91 9948298322 +91 9948298422 Fax: +91 40 23544007 E-mail: [email protected] Website: www.indimmune.com

15. Krebs Biochem Krebs Biochemicals & Industries Limited (KBIL) was founded in 1991.It aims at developing biotech processes with commercial application in the fields of medicine and agriculture industry. In 1994 it went public to part finance its fermentation technology project. In 2006, it achieved sales turnover of Rs. 3,189 lacs and exports worth Rs. 1,352 lacs. Krebs Biochem’s manufacturing units located at Regadichelika Village, Nellore Dist., Andhra Pradesh produce Pseudoephedrine, Ephedrine and other salts used for making formulations for respiratory ailments, viz., cough, cold, etc. It got USFDA and EDQM approval in 2003 and renewed its WHO-GMP certificate in 2005 Board of Directors Dr.M.Venkataratnam. IAS (retd), Chairman Dr.B.Brahmaiah, IDBI nominee Mrs.Sangeetha Sharma, Exim Bank nominee Mr.M.Venkateswara Rao, APIDC nominee: Dr.T.Kuchroo, Independent Directors Mr.G.V.L.Prasad, Independent Directors Mr.K.S.S.Prasad (small shareholders director) Independent Directors Dr. R T Ravi, Managing Director Products: Synthetic Lavastatin Simvastatin I - Ephedrochiloride d - Pseudoephedrine Hydrochloride dl - Ephedrine Base

Herbal Calcium Sennosides - 20% & 60% Garcinia Combogia Powdered Extract Capsaicin - 50/100 Intermediates Crude Lovastatin Simvastatin Ammonium Salt Contact Address: Krebs Biochemicals & Industries Limited #401/402, 4th Floor, Cyber Heights, Plot No 13, Road No 2, Banjara Hills, Hyderabad - 500033 Andhra Pradesh India Phones: +91-040-23540415 +91-040-23540416 +91-040-23541278 +91-040-55593175 Fax: +91-040-23540320 E-mail: [email protected] Website: www.krebsbiochem.com

16. Metahelix Life Sciences With a venture capital of US$ 1.5 million, Metahelix Life Sciences Private Limited was founded by five scientists, viz. K. K. Narayanan, Gautham Nadig, Suri Venkatachalam, Ganesh Kishore, and Himadri Pakrasi in December 2000 at Bangalore, India. It was established with the aim of gene discovery for agronomic and nutritional enhancement of food and commercial crops. Scientific consulting and contract research in life science informatics and functional genomics are its areas of specialization. It also provides algorithm design and software development for various applications in bioinformatics. Its headquarters is in Bangalore, India. It has employee strength of about 40 scientists. In 2003, Metahelix had signed a four-year genomic research agreement with ViaLactia BioSciences (NZ) Ltd., a dairy biotechnology company. The research aims at providing functional validation of a number of genes from pasture plants. The programme has the potential to produce improved plant varieties of pasture and crop plants. Board of Directors K. K. Narayanan (Managing Director) Gautham Nadig (Director) Ravi Krishna (President -Seeds) Vasudeva Rao (President -Ag Technologies)

S.no

Job Title Qualifications Experience

Job Responsibility

1

Research Associate/Junior Scientist (Genomics)

M.Sc ( Plant Breeding & Genetics)/ Biotechnology

1-3 yrs

The incumbent shall be responsible for plant

tissue culture and transformation works

2 Assistant Breeder(Cotton)

M.Sc in Plant Breeding and Genetics. PhD preferred

To assist Cotton Breeder in cotton breeding activities of the company

3 Assistant Breeder(Rice)

UG - B.Sc - Agriculture, PG - M.Sc - Agriculture, PPG - Ph.D/Doctorate - Agriculture

3-5 years

To assist the Rice breeder in rice breeding activities of the company

4 Assistant Breeder(Maize

UG - B.Sc - Agriculture, PG - M.Sc - Agriculture, PPG - Ph.D/Doctorate - Agriculture

3 to 5 yrs

To assist the Crop Lead in Maize Breeding activities. Should have hands on experience for a period of 2 to 5 years in Maize Breeding activities.

5 Trainees in Plant Breeding

UG - B.Sc - Agriculture,

0-1 years

PG - M.Sc - Agriculture, PPG - Ph.D/Doctorate - any specialization

6 Parent Seeds Officers

UG - B.Sc - Agriculture, PG - M.Sc - Agriculture, PPG - Any Ph.D / Doctorate / M.Phil. - Any Specialization

Minimum 2 to 4 years experience in Parent seed production activities in reputed Agri-biotech Seed Companies

Responsible for Parent seeds production activities.

7 Okra Breeder

UG - B.Sc - Agriculture, PG - M.Sc - Agriculture, PPG – Ph.D / Doctorate / M.Phil. Not Required

5-8 years

Responsible for Okra Breeding activity and to develop commercial production of high quality Okra hybrids.

Contact Information for Job Openings: Name Mr. B Girish Kumar Telephone 9880341522, 91-080-7870236, 7836086 Fax: 7836084 Website http://www.meta-helix.com Products: Genomics Plant Transformation and Trait Development Functional Genomics Genetic Purity Testing Marker Development Computational Biology Protein Informatics Protein Structure Modeling Modeling and Simulation of Cellular Processes Contact Address: Metahelix Life Sciences Pvt. Ltd Plot No. 3, KIADB 4th Phase, Bommasandra Industrial Area, Bangalore 560 099 Tel: +91-80-783 6086 Fax: +91-80-783 6084 email: [email protected] Website: www.meta-helix.com

17. Wipro Biomed Wipro Biomed, formed in 1988, is a US$ 2 billion biomedical business division of Wipro Limited. It has 3 businesses: Diagnostics System Group, Life Science Group and Medical Systems Group. It has 7 offices and employee strength of about 80. Wipro Biomed has networked and interconnected offices so as to have flawless communication with its customers. It has 45 distribution centres and more than 1500 customers. It has 8 teams in diagnostics and research and 23 support teams. It offers services in life sciences, clinical diagnostics and medical systems. With a growth rate of 18.5%, Wipro Biomed had achieved business of Rs. 61.8 crore in 2005. In 2006, it entered into strategic alliance with CiPhergen BioSystems Inc. to market ProteinChip Systems and Solutions, products of Ciphergen, in India, Bangladesh, Sri Lanka and Nepal. Board of Directors Varsha Anand, Vice President Diwakar Virnave, Head - Services and Medical divisions Dipak Banerjee, Head - Strategic Accounts (Diagnostics Division) Rajnish Bharti, Head - Life Science Business (Lab) Bhupendra Chaudhary, Business Head (Diagnostics Group) Joy Joseph, Chief Scientific Officer & Business Manager Specialty Products

Contact Address: Wipro Biomed, C Block, Ground Floor, Sarjapur Campus- 1 Doddakannelli, Sarjapur Road, Bangalore – 560035 Phone: 28440011/ 28440376 Fax: 080- 28440367 Email: [email protected] Website: www.wiprobiomed.in